Vertex buys Crinetics for $10bn in endocrinology drive
Vertex has made the largest acquisition in its history, agreeing to buy Crinetics in a $10bn deal that adds an approved therapy for acromegaly.
Crinetics Pharmaceuticals
NASDAQ: CRNX $84.95 USD
Crinetics Pharmaceuticals is a public biopharmaceutical company developing and commercializing oral, small-molecule therapies for endocrine diseases and endocrine-related tumors.
Company Info
Sector:Endocrine Disease Therapeutics
Headquarters:San Diego, California, USA
Founded:2008
Website:crinetics.com/
Clinical Development Pipeline
Paltusotine
Target: Somatostatin receptor type 2Recent News
Vertex to acquire Crinetics in $10B foray into endocrine disease drugs
BioPharma Dive reports: Vertex to acquire Crinetics in $10B foray into endocrine disease drugs.
Leadership Team
Scott Struthers
President and Chief Executive Officer